

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in this application.

1 – 46. (cancelled)

47. (previously presented) A chimeric, humanized or human antibody comprising a heavy chain variable region defined by SEQ ID NO: 2 and a light chain variable region defined by SEQ ID NO: 3.

48. (previously presented) A chimeric, humanized or human antibody comprising a heavy chain variable region defined by SEQ ID NO: 4 and a light chain variable region defined by SEQ ID NO: 5.

49. (previously presented) A chimeric, humanized or human antibody comprising a heavy chain variable region defined by SEQ ID NO: 12 and a light chain variable region defined by SEQ ID NO: 14.

50. (previously presented) The antibody of claim 49, wherein the antibody is an antigen binding fragment that is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.

51. (previously presented) The antibody of claim 49, wherein the antibody is conjugated to an effector moiety.

52. (previously presented) A pharmaceutical composition comprising the antibody of claim 49 and a pharmaceutically acceptable excipient.